Larry Cohen, MD
Family Medicine · Philadelphia, PANPI 1013992957
Payments from drug & device makers
Across 355 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$853
- Novo Nordisk$648
- Lilly USA, LLC$508
- Amgen$432
- AstraZeneca$413
- Johnson & Johnson$356
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,610100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $853 |
| Novo Nordisk | 42 | $648 |
| Lilly USA, LLC | 29 | $508 |
| Amgen(2 entities) | 30 | $432 |
| AstraZeneca | 28 | $413 |
| Johnson & Johnson | 18 | $356 |
| Merck | 22 | $300 |
| Boehringer Ingelheim | 19 | $298 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $207 |
| Pfizer | 11 | $191 |
| Abbott | 7 | $139 |
| Astellas Pharma US Inc | 8 | $135 |
| Sanofi-aventis U.S. LLC | 7 | $111 |
| Exact Sciences | 6 | $104 |
| Bayer | 5 | $93 |
| Inspire Medical Systems, Inc. | 4 | $80 |
| Novartis | 5 | $75 |
| Amarin Pharma, Inc. | 5 | $68 |
| Dexcom, Inc. | 4 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Radius Health, Inc. | 4 | $55 |
| Teva Pharmaceuticals USA, Inc. | 4 | $54 |
| IBSA Pharma Inc. | 2 | $47 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| GSK | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Eisai Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Seqirus USA Inc | 1 | $17 |
| Stimwave Technologies Incorporated | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$5,616 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 105 | $113,031 |
| EliquisApixaban | 107 | $91,307 |
| OzempicSemaglutide | 63 | $74,886 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $56,026 |
| MounjaroTirzepatide | 22 | $39,816 |
| TrulicityDulaglutide | 26 | $35,425 |
| XareltoRivaroxaban | 99 | $34,860 |
| FarxigaDapagliflozin Propanediol | 37 | $33,355 |
| JanuviaSitagliptin Phosphate | 30 | $32,970 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $28,506 |
| Spiriva RespimatTiotropium Bromide | 41 | $23,341 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $18,738 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,863 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $10,522 |
| TradjentaLinagliptin | 17 | $8,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat | $298 | $151,202176 claims |
| PfizerEliquis | $191 | $91,307107 claims |
| Lilly USA, LLCMounjaro, Trulicity | $508 | $75,24048 claims |
| Novo NordiskOzempic | $648 | $74,88663 claims |
| MerckJanuvia, Janumet, Dulera | $300 | $57,86069 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $35 | $40,36987 claims |
| AstraZenecaFarxiga, Symbicort | $413 | $36,38048 claims |
| Johnson & JohnsonXarelto | $356 | $34,86099 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $37 | $8,82712 claims |
| AbbVieSynthroid | $853 | $3,86642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Daniel LinPhiladelphia$392K
- Glenn RosenPhiladelphia$367K
- Christopher ChambersPhiladelphia$350K
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.